Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
